Cargando…

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

BACKGROUND: Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimbursement decisions on OMPs are complex, and there is a need for more transparent processes to know which criteria should be considered to inform these decisions. This study aimed to determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Andrés-Nogales, Fernando, Cruz, Encarnación, Calleja, Miguel Ángel, Delgado, Olga, Gorgas, Maria Queralt, Espín, Jaime, Mestre-Ferrándiz, Jorge, Palau, Francesc, Ancochea, Alba, Arce, Rosabel, Domínguez-Hernández, Raquel, Casado, Miguel Ángel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073956/ https://www.ncbi.nlm.nih.gov/pubmed/33902672 http://dx.doi.org/10.1186/s13023-021-01809-1

Ejemplares similares

Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
por: Guarga, Laura, et al.
Publicado: (2019)

Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
por: Kolasa, Katarzyna, et al.
Publicado: (2016)

Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
por: Gasol, Montse, et al.
Publicado: (2022)

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017)

Development and pilot of a multicriteria decision analysis (MCDA) tool for health services administrators
por: Blythe, Robin, et al.
Publicado: (2019)

A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt
por: Elezbawy, Baher, et al.
Publicado: (2022)

Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps
por: Frazão, Talita D. C., et al.
Publicado: (2018)

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
por: Zozaya, Néboa, et al.
Publicado: (2022)

Crystallographic and Spectroscopic Insights into Heme Degradation by Mycobacterium tuberculosis MhuD
por: Graves, Amanda B., et al.
Publicado: (2014)

Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa
por: Miot, Jacqui, et al.
Publicado: (2012)

Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
por: Xiang, Gao, et al.
Publicado: (2023)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

Optimized landfill site selection for municipal solid waste by integrating GIS and multicriteria decision analysis (MCDA) technique, Hossana town, southern Ethiopia
por: Doboch Wanore, Tesfaye, et al.
Publicado: (2023)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021)

Ventanillas de Salud (VDS) and Mobile Health Units (MHU): A binational collaborative models
por: Rangel Gómez, María Gudelia, et al.
Publicado: (2022)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
por: Tony, Michèle, et al.
Publicado: (2011)

Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context
por: Wagner, Monika, et al.
Publicado: (2018)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
por: Garau, Martina, et al.
Publicado: (2017)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Appraising research policy instrument mixes: a multicriteria mapping study in six European countries of diagnostic innovation to manage antimicrobial resistance
por: Coburn, Josie, et al.
Publicado: (2021)

Structure–function characterization of the mono- and diheme forms of MhuD, a noncanonical heme oxygenase from Mycobacterium tuberculosis
por: Snyder, Samuel N., et al.
Publicado: (2021)

Supplier selection: an MCDA-based approach
por: Mukherjee, Krishnendu
Publicado: (2017)

Panel discussion on the application of MCDA tools
por: Watson, Michael
Publicado: (2018)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Multicriteria optimization
por: Ehrgott, Matthias, et al.
Publicado: (2000)

MCDA or preference-based social welfare functions?
por: Sevilla, J. P.
Publicado: (2018)

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
por: Baran-Kooiker, Aleksandra, et al.
Publicado: (2018)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
por: Ward, Leanne Marie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hf4duoasn9v52f1mogp3bpmb9b